Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.

Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression

Abstract

Background Maintenance treatment to prevent recurrences is recommended for chronic forms of major depressive disorder (MDD), but few studies have examined maintenance efficacy of antidepressants with chronic MDD. This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD. Methods A total of 165 outpatients with chronic, nonpsychotic MDD, MDD plus dysthymic disorder ("double-depression"), or recurrent MDD with incomplete inter-episode recovery, who achieved and maintained a clinical response during acute and continuation treatment with either nefazodone alone or nefazodone combined with psychotherapy, were randomized to 52 weeks of double-blind nefazodone (maximum dose 600 mg/day) or placebo. The occurrence of major depressive episodes during maintenance treatment was assessed with the 24-item Hamilton Rating Scale for Depression, a DSM-IV MDD checklist, and a blinded review of symptom exacerbations by a consensus committee of research clinicians. Results Application of a competing-risk model that estimated the conditional probability of recurrence among those patients remaining on active therapy revealed a significant (p =.043) difference between nefazodone (n = 76) and placebo (n = 74) when the latter part of the 1-year maintenance period was emphasized. At the end of 1 year, the conditional probability of recurrence was 30.3% for nefazodone-treated patients, compared with 47.5% for…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0006-3223(02)01971-6

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 66 references

Research works printed but not linked: 3

  1. Fawcett, 1987, Clinical management—imipramine/placebo administration manual, Psychopharmacology Bull, 23, 309
  2. Klein, 1998, Thirty-month naturalistic follow-up study of early-onset dysthymic disorder, J Abnorm Psychol, 107, 338, 10.1037/0021-843x.107.2.338 · doi:10.1037/0021-843x.107.2.338
  3. Robinson, 1996, The safety profile of nefazodone, J Clin Psychiatry, 57, 31

Cited by

See all 77

Metadata

Authors
Gelenberg, A. J., Trivedi, M. H., Rush, A. J., Thase, M. E., Howland, R., Klein, D. N., Kornstein, S. G., Dunner, D. L., Markowitz, J. C., Hirschfeld, R. M. A., Keitner, G. I., Zajecka, J., Kocsis, J. H., Russell, J. M., Miller, I., Manber, R., Arnow, B., Rothbaum, B., Munsaka, M., Banks, P., Borian, F. E., & Keller, M. B.
Affiliations
  • University of Arizona (US)
  • The University of Texas Southwestern Medical Center (US)
  • University of Pittsburgh (US)
  • Stony Brook University (US)
  • Virginia Commonwealth University Medical Center (US)
  • Cornell University (US)
  • The University of Texas Medical Branch at Galveston (US)
  • Brown University (US)
  • Rush University Medical Center (US)
  • Stanford University (US)
  • Emory University (US)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
Gelenberg, Alan J.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2003-10
Volume
54
Issue
8
Pages
806-817
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2083904174
Cited by
76
References
66
Citations by year
2025: 1 · 2024: 2 · 2022: 1 · 2021: 2 · 2019: 2 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 7 · 2013: 6 · 2012: 3
FWCI
4.29
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (U01MH061590)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
nefazodone, maintenance therapy, depression recurrence prevention, double depression, dysthymia, antidepressant efficacy, psychotherapy adjunct, sleepiness, adverse events, competing risk model
MeSH terms
Acute Disease, Adolescent, Adult, Aged, Chronic Disease, Combined Modality Therapy, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Eligibility Determination, Female, Humans, Male, Middle Aged, Piperazines, Psychotherapy, Recurrence, Substance Withdrawal Syndrome, Triazoles, Cross-Over Studies, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. https://app.cochat.ai/papers/10.1016/s0006-3223(02)01971-6
The paper
Gelenberg, A. J., Trivedi, M. H., Rush, A. J., Thase, M. E., Howland, R., Klein, D. N., Kornstein, S. G., Dunner, D. L., Markowitz, J. C., Hirschfeld, R. M. A., Keitner, G. I., Zajecka, J., Kocsis, J. H., Russell, J. M., Miller, I., Manber, R., Arnow, B., Rothbaum, B., Munsaka, M., . . . Keller, M. B. (2003). Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry. https://doi.org/10.1016/s0006-3223(02)01971-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.